The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) on April 7, 2026, adopted a set of new recommendations aimed at enhancing drug safety monitoring across the European Union. The recommendations, which target national competent authorities and marketing authorization holders, propose stricter requirements for the reporting of adverse drug reactions and the implementation of risk management plans. The move is expected to impact pharmaceutical companies, national regulators, healthcare professionals, and patients by increasing the volume of safety data to be collected and analyzed.
The recommendations were issued as a formal opinion by PRAC, a committee within EMA responsible for assessing and monitoring the safety of medicines. While the recommendations are non-binding, they carry significant weight in EU pharmaceutical governance and are expected to influence future regulatory guidelines and national legislation.
Policy Orientations and Trade-offs
increasing the frequency and granularity of adverse reaction reporting, and strengthening the requirements for risk management plans. Specifically, the committee calls for quarterly rather than biannual submission of periodic safety update reports for certain high-risk medicines, and for more detailed data on patient subgroups, such as the elderly and pregnant women. The trade-off involves a moderate increase in administrative burden for pharmaceutical companies and national regulators, balanced against potential improvements in patient safety through earlier detection of safety signals.
Impact on Stakeholders For pharmaceutical companies, the new recommendations imply higher compliance costs due to more frequent reporting and the need to expand data collection systems. National competent authorities in EU member states will face increased workload in reviewing additional safety reports, potentially requiring additional staff or resources. Healthcare professionals may benefit from more timely safety information, enabling better-informed prescribing decisions. Patients, particularly those using high-risk medicines, could experience improved safety outcomes, though the direct impact is contingent on effective implementation by regulators and industry.
Expected Institutional Follow-up The recommendations will now be transmitted to the European Commission, which may incorporate them into binding implementing measures under the EU pharmacovigilance legislation. National authorities are expected to align their practices with the recommendations, and EMA will monitor implementation through its pharmacovigilance audits. The committee also plans to review the impact of the recommendations within two years.
← Atlas › News › Health & Lifestyle